Clinical Research
Along with normal clinical service, wide range of clinical trials also provided in our center
We collaborate with academics and clinicians in Department of Medicine, Department of Surgery, Department of Clinical Oncology and Clinical Trial Centre in conducting cutting-edge clinical trials to cancer patients.
We are actively recruiting patient to participate in the following clinical trials
Please send referral letter to medicaloncology@hku.hk if interested
Recruiting Clinical Trials
Liver Cancer
Protocol Number
Protocol Title
Experimental Agent
Principle Investigator
OTX-2002-101
A Phase 1/2 open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of OTX-2002 as a single agent and in combination with standard of care in patients with hepatocellular carcinoma and other solid tumor types known for association with the MYC oncogene.
OTX-2002
Breast Cancer
Protocol Number
Protocol Title
Experimental agent
Principle Investigator
CLEE011O12001 (ADJUVANT WIDER)
A phase IIIb study to characterize the effectiveness and safety of Adjuvant ribociclib in wide patient populations with HR+ HER2- early breast cancer
Ribociclib + AI
OBI-822-011
The GLORIA Study: A Phase 3, Randomized, Open-Label Study of the Anti-Globo H Vaccine Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients with High-Risk, Early-Stage Globo H-Positive Triple Negative Breast Cancer
OBI-822, OBI-821
VS
Placebo
J2J-MC-JZLH (Ember-04)
A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+,HER2- Early Breast Cancer with an Increased Risk of Recurrence
Imlunestrant
VS
AI
CO44657 (PionERA)
A Phase III, randomized, open-label study evaluating efficacy and safety of giredestrant compared with fulvestrant,bboth combined with a cdk4/6 inhibitor, in patients with estrogen receptor-positive, her2-negative advanced breast cancer with resistance to prior adjuvant endocrine therapy
Giredestrant + CDK4/6
VS
Fulvestrant + CDK4/6
OP-1250-301
(Opera-01)
A phase 3 randomized, open-label study of OP-1250 monotherapy vs standard of care for the treatment of ER+, HER2- advanced or metastatic breast cancer following endocrine and CDK4/6 inhibitor therapy (OPERA-01)
OP-1250
VS
Treatment of Physician's Choice (TPC)
DB1303-O-3002
A Phase 3, Randomized, Multi-center, Open-label Study of DB-1303 Versus Investigator’s
Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low, Hormone
Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on
Endocrine Therapy
DB-1303
VS
Physician choice of chemotherapy
Lung Cancer
Protocol Number
Protocol Title
Experimental agent
Principle Investigator
MK-7684A-003
A Phase 3, Multicenter, Randomized, Double-Blind Study of MK-7684 with Pembrolizumab as a Coformulation (MK-7684A) Versus Pembrolizumab Monotherapy as First Line Treatment for Participants With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer
MK-7684A (vibostolimab + pembrolizumab)
GS-US-624-6376
(Velocity 01/02)
A Phase 2 Platform Study Evaluating the Safety and Efficacy of Novel Treatment Combinations in Patients with Lung Cancer
Novel Treatment combination
475-0708 MT Lung
A Phase 2 Open-label Single-arm Study to Evaluate the Combination of Pembrolizumab, Lenvatinib and Chemotherapy in Non-small Cell Lung Cancer (NSCLC) Harbouring Targetable Mutation and Failed Standard Tyrosine Kinase Inhibitors
Pembrolizumab + Lenvatinib + Pemetrexed + Carboplatin
Genitourinary
Protocol Number
Protocol Title
Experimental agent
Principle Investigator
XL092-304
A Phase 3 Randomized Open-Label study of XL092 + Nivolumab vs Sunitinib
XL092 + Nivolumab
VS
Sunitinib
A Phase 3, Open Label, Randomised, 3-Arm, Multi-Centre Study of Savolitinib plus Durvalumab versus Sunitinib and Durvalumab Monotheraphy in Participants with MET-Driven, Unresectable and Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (PRCC) (SAMETA)
durvalumab and savolitinib
vs
durvalumab
vs
sunitinib
Colorectal Cancer
Protocol Number
Protocol Title
Experimental Agent
Principle Investigator
20210081 (CodeBreaK 301)
Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
Sotorasib+Panitumumab + FOLFIRI
VS
Bevacizumab + FOLFIRI
Other Solid Tumor
Protocol Number
Protocol Title
Experimental agent
Principle Investigator
STARTRK-2
An Open-Label, Multicenter, Global Phase2 Basket Study of Entrectinib for the treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Entrectinib
TIDENT-1
(TPX-0005-01)
Phase 2 Study
NTRK1/2/3-/ROS-1/ALK-rearranged solid tumors
Repotrectinib
Phase 1 Study
Protocol Number
Protocol Title
Experimental agent
Principle Investigator
A001 (Abrele)
A Phase 1, first-in-human study of ARB202, bispecific antibody to CDH17 and CD3 in advanced gastrointestinal malignancies
ARB202
NEI01-20001
A 2-part, First-in-patient, Open-label, Dose-escalation and Expansion Cohort Study of NEI-01 as Monotherapy in Patients With Advanced Solid Tumors or Relapsed/Refractory Acute Myeloid Leukemia
NEI-01
4003.1
A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of a Study Drug in Subjects With Advanced Solid Tumors
HBM4003
RLY-4008-101
A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors
RLY-4008
Gastrointestinal Cancer
Protocol Number
Protocol Title
Experimental Agent
Principle Investigator
D9802C00001
A Phase 3 Multi-center, Open-label,Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared with Investigator’s Choice of Therapy in Second- or Later-Line Adult Participants with Advanced/Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing Claudin 18.2
AZD0901
VS
Investigator choice of therapy
Dr. Gerry Kwok
Bile Duct Cancer
Protocol Number
Protocol Title
Experimental agent
Principle Investigator
Upcoming...